COX inhibitors for airway inflammation

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 2, 2012, Pages 195-207

  Malhotra, Sanjay ^a   Deshmukh, Sangram Shesharao ^a   Dastidar, Sunanda Ghosh ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Arachidonic acid; COPD.; Cycloxygenase; NSAID; Prostacyclin; Prostaglandin; Thromboxane

Indexed keywords

ACROLEIN; ARACHIDONIC ACID; CIGARETTE SMOKE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INTERLEUKIN 1; LIPOPOLYSACCHARIDE; OXIDIZING AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOXANE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC RHINITIS; ASTHMA; CATALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; ENZYME INHIBITION; ENZYME STRUCTURE; ENZYME SYNTHESIS; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESPIRATORY TRACT DISEASE; REVIEW; SIGNAL TRANSDUCTION; STEREOCHEMISTRY;

ANIMALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; HUMANS; LIPID METABOLISM; PNEUMONIA;

EID: 84857412262     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.661416     Document Type: Review

References (107)

1. Wenzel SE. Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacotherapy 1997;17:3S-12
2. Henderson WR Jr. Role of leukotrienes in asthma. Ann Allergy 1994;72:272-8
3. O'Byrne PM. Leukotrienes in the pathogenesis of asthma. Chest 1997;111:27S-34
4. Rubin P, Mollison KW. Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids. Prostaglandins Other Lipid Mediat 2007;83:188-97
5. Rolina S, Masereela B. DogneJ-M. Prostanoids as pharmacological targets in COPD and asthma. Eur J Pharmacol 2006;533:89-100
6. Carey MA, Germolec DR, Langenbach R, Zeldin DC. Cyclooxygenase enzymes in allergic inflammation and asthma. Prostaglandins Leukot Essent Fatty Acids 2003;69:157-62
7. Sousa AR, Pfister R, Christie PE, et al. Enhanced expression of cyclo-oxygenase 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin sensitive asthma. Thorax 1997;52:940-5
8. Pang L, Pitt A, Petkova D, Knox AJ. The COX-1/COX-2 balance in asthma. Clin Exp Allergy 1998;28:1050-8
9. Montuschi P, Peters-Golden ML. Leukotriene modifiers for asthma treatment. Clin Exp Allergy2010;40:1732-41
10. Montuschi P, Macagno F, Parente P, et al. Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD. Thorax 2005;60:827-33
11. Mitchell JA, Warner TD. Cyclooxygenase- 2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 1999;128:1121-32
12. Ramalho TC, Rocha MVJ, da Cunha EFF, Freitas MP. The search for new COX-2 inhibitors: a review of 2002 - 2008 patents. Expert Opin Ther Patents 2009;19:1-36
13. Schuligoi R, Sedej M, Waldhoer M, et al. Prostaglandin H2 induces the migration of human eosinophils through the chemoattractant receptor homologous molecule of Th2 cells, CRTH2. J Leukoc Biol 2009;85:136-45
14. Graf BA, Nazarenko DA, Borrello MA, et al. Biphenotypic B/macrophage cells express COX-1 and up-regulate COX- 2 expression and prostaglandin E(2) production in response to pro-inflammatory signals. Eur J Immunol 1999;29:3793-803
15. Mitchell JA, Evans TW. Cyclooxygenase-2 as a therapeutic target. Inflamm Res 1998;47:S88-92
16. Abramovitz M, Metters KM. Prostanoid receptors. Ann Rep Med Chem 1998;33:223-31
17. Hardy CC, Bradding P, Robinson C, Holgate ST. Bronchoconstrictor and antibronchoconstrictor properties of inhaled prostacyclin in asthma. J Appl Physiol 1988;64:1567-74
18. Mathe AA, Hedqvist P. Effect of prostaglandins F2alpha and E2 on airway conductance in healthy subjects and asthmatic patients. Am Rev Respir Dis 1975;111:313-20
19. Hardy CC, Robinson C, Tattersfield AE, Holgate ST. The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men. N Engl J Med 1984;311:209-13
20. Hamberg M, Samuelsson B. On the mechanism of the biosynthesis of prostaglandins E1 and F1alpha. J Biol Chem 1967;242:5336-43
21. Goodwin DC, Gunther MH, Hsi LH, et al. Nitric oxide trapping of tyrosyl radicals generated during prostaglandin endoperoxide synthase turnover. Detection of the radical derivative of tyrosine 385. J Biol Chem 1998;273:8903-9
22. Malkowski MG, Ginell SL, Smith WL, Garavito RM. The productive conformation of arachidonic acid bound to prostaglandin synthase. Science 2000;289:1933-7
23. Tsai AL, Palmer G, Xiao G, et al. Structural characterization of arachidonyl radicals formed by prostaglandin H synthase-2 and prostaglandin H synthase-1 reconstituted with mangano protoporphyrin IX. J Biol Chem 1998;273:3888-94
24. Dean AM, Dean FM. Carbocations in the synthesis of prostaglandins by the cyclooxygenase of PGH synthase? A radical departure!. Protein Sci 1999;8:1087-98
25. Miyamoto T, Ogino M, Yamamoto S, Hayaishin O. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem 1976;259:2629-36
26. DeWitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 1988;85:1412-16
27. Merlie JP, Fagan D, Mudd J, Needleman P. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). J Biol Chem 1988;263:3550-3
28. Yokoyama C, Takai T, Tanabe T. Primary structure of sheep prostaglandin endoperoxide synthase deduced from cDNA sequence. FEBS Lett 1988;231:347-51
29. Masferrer JL, Zweifel BS, Seibert K, Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 1990;86:1375-9
30. Xie WL, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-6
31. Kujubu DA, Herschman HR. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem 1992;267:7991-4
32. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Ann Rev Biochem 2000;69:145-82
33. Smith WL, DeWitt DL. Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol 1996;62:167-215
34. Demoly P, Jaffuel D, Lequeux N, et al. Prostaglandin H synthase 1 and 2 immunoreactivities in the bronchial mucosa of asthmatics. Am J Respir Crit Care Med 1997;155:670-5
35. Bonner JC, Rice AB, Ingram JL, et al. Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis. Am J Pathol 2002;161:459-70
36. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat Rev Biol 1971;231:232-5
37. Fu JY, Masferrer JL, Seibert K, et al. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human. J Biol Chem 1990;265:16737-40
38. Xie W, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-6
39. Kujubu DA, Fletcher BS, Varnum BC, et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-72
40. O'Banion MK, Sadowski HB, Winn V, Young DA. A serum- and glucocorticoid-regulated 4 kb mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991;266:23261-7
41. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994;91:3228-32
42. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor. Arthritis Rheum 1998;41:1591-602
43. Pang L, Knox AJ. Effect of interleukin-1 beta, tumour necrosis factor-alpha and interferon-gamma on the induction of cyclooxygenase-2 in cultured human airway smooth muscle cells. Br J Pharmacol 1997;121:579-87
44. Lazzeri N, Belvisi MG, Patel HJ, et al. Effects of prostaglandin E2 and cAMP elevating drugs on GM-CSF release by cultured human airway smooth muscle cells: relevance to asthma therapy. Am J Respir Mol Cell Biol 2001;24:44-8
45. McKay S, Sharma HS. Autocrine regulation of asthmatic airway inflammation: role of airway smooth muscle. Respir Res 2002;3:11-23
46. Montuschi P, Curro D, Ragazzoni E, et al. Anaphylaxis increases 8-iso-prostaglandin F2alpha release from guinea-pig lung in vitro. Eur J Pharmacol 1999;365:59-64
47. Morham SG, Langenbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995;83:473-82
48. Gavett SH, Madison SL, Chulada PC, et al. Allergic lung responses are increased in prostaglandin H synthase-deficient mice. J Clin Invest 1999;104:721-32
49. Zeldin DC, Wohlford-Lenane C, Chulada P, et al. Airway inflammation and responsiveness in prostaglandin H synthase-deficient mice exposed to bacterial lipopolysaccharide. Am J Respir Cell Mol Biol 2001;25:457-65
50. Mitchell JA, Belvisi MG, Akarasereenont P, et al. Induction of cyclooxygenase 2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol 1994;113:1008-14
51. Vigano T, Habib A, Hernandez A, et al. Cyclooxygenase-2 and synthesis of PGE2 in human bronchial smooth muscle cells. Am J Respir Crit Care Med 1997;155:864-8
52. Taha R, Olivenstein R, Utsumi T, et al. Prostaglandin H synthase 2 expression in airway cells from patients with asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:636-40
53. Fujimura M, Kamio Y, Kasahara K, et al. Prostanoids and cough response to capsaicin in asthma and chronic bronchitis. Eur Respir J 1995;8:1499-505
54. Ishiura Y, Fujimura M, Yamamoto H, et al. COX-2 Inhibition attenuates cough reflex sensitivity to inhaled capsaicin in patients with asthma. J Investig Allergol Clin Immunol 2009;19:370-4
55. Hay DWP, Trophy TJ, Undem BJ. Cysteinyl-leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol Sci 1995;16:304-9
56. Griffin M, Weiss JW, Leitch AG, et al. Effects of leukotriene D on the airways in asthma. N Engl J Med 1983;308:436-9
57. Laitinen LA, Laitinen A, Haahtela T, et al. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 1993;341:989-90
58. Pavord ID, Tatterfield AE. Bronchoprotective role for endogenous prostaglandin E2. Lancet 1995;345:436-8
59. Curzen N, Rafferty P, Holgate ST. The effect of flurbiprofen, a cyclooxygenase inhibitor, and terfenadine, alone and in combination, on allergen-induced immediate bronchoconstriction. Thorax 1987;42:946-52
60. Matsuoka T, Hirata M, Tanaka H, et al. Prostaglandin D2 as a mediator of allergic asthma. Science 2000;287:2013-17
61. Hirai H, Tanaka K, Yoshie O, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001;193:255-62
62. Montuschi P, Kharitonov SA, Ciabattoni G, Barnes PJ. Exhaled leukotrienes and prostaglandins in COPD. Thorax 2003;58:585-8
63. Montuschi P, Martello S, Felli M, et al. Liquid chromatography/mass spectrometry analysis of exhaled leukotriene B4 in asthmatic children. Respir Res 2005;6:119
64. O'Sullivan S, Dahlen SE, Larsson K, et al. Exposure of healthy volunteers to swine house dust increases formation of leukotrienes, prostaglandin D2, and bronchial responsiveness to methacholine. Thorax 1998;53:1041-6
65. Bochenek G, Nizankowska E, Gielicz A, et al. Plasma 9alpha,11-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma. Thorax 2004;59:459-64
66. Monneret G, Gravel S, Diamond M, et al. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 2001;98:1942-8
67. Emery DL, Djokic TD, Graf PD, Nadel JA. Prostaglandin D2 causes accumulation of eosinophils in the lumen of the dog trachea. J Appl Physiol 1989;67:959-62
68. Woodward DF, Hawley SB, Williams LS, et al. Studies on the ocular pharmacology of prostaglandin D2. Invest Ophthalmol Vis Sci 1990;31:138-46
69. Oguma T, Asano K, Shiomi T, et al. Cyclooxygenase-2 expression duringallergic inflammation in guinea-pig lungs. Am J Respir Crit Care Med 2002;165:382-3
70. Gervais FG, Cruz RP, Chateauneuf A, et al. Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP. J Allergy Clin Immunol 2001;108:982-8
71. Yang C-M, Lee I-T, Lin C-C, et al. Cigarette smoke extract induces COX-2 expression via a PKCalpha/c-Src/ EGFR, PDGFR/PI3K/Akt/NF-kappaB pathway and p300 in tracheal smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2009;297:892-902
72. Moodie FM, Marwick JA, Anderson CS, et al. Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-kB activation and proinflammatory cytokine release in alveolar epithelial cells. FASEB J 2004;18:1897-9
73. Van der TM, Rezayat D, Kauffman HF, et al. Lipid-soluble components in cigarette smoke induce mitochondrial production of reactive oxygen species in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2009;297:L109-14
74. Stavrides JC. Lung carcinogenesis: pivotal role of metals in tobacco smoke. Free Radic Biol Med 2006;41:1017-30
75. Park YS, Kim J, Misonou Y, et al. Acrolein induces cyclooxygenase-2 and prostaglandin production in human umbilical vein endothelial cells: roles of p38 MAP kinase. Arterioscler Thromb Vasc Biol 2007;27:1319-25
76. Moretto N, Facchinetti F, Southworth T, et al. Unsaturated aldehydes contained in cigarette smoke elicit IL-8 release in pulmonary cells through mitogen-activated protein kinases. Am J Physiol Lung Cell Mol Physiol 2009;296:L839-48
77. Martey CA, Baglole CJ, Gasiewicz TA, et al. The aryl hydrocarbon receptor is a regulator of cigarette smoke induction of the cyclooxygenase and prostaglandin pathways in human lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 2005;289:L391-9
78. Hirst SJ, Martin JG, Bonacci JV, et al. Proliferative aspects of airway smooth muscle. J Allergy Clin Immunol 2004;114:S2-17
79. Howarth PH, Knox AJ, Amrani Y, et al. Synthetic responses in airway smooth muscle. J Allergy Clin Immunol 2004;114:S32-50
80. Ito K, Caramori G, Adcock IM. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. J Pharmacol Exp Ther 2007;321:1-8
81. Koyasu S. The role of PI3K in immune cells. Nat Immunol 2003;4:313-19
82. Hsieh HL, Wu CB, Sun CC, et al. Sphingosine-1-phosphate induces COX-2 expression via PI3K/Akt and p42/p44 MAPK pathways in rat vascular smooth muscle cells. J Cell Physiol 2006;207:757-66
83. Jorgensen E, Stinson A, Shan L, et al. Cigarette smoke induces endoplasmic reticulum stress and the unfolded protein response in normal and malignant human lung cells. BMC Cancer 2008;8:229
84. Xu K, Kitchen CM, Shu HK, Murphy TJ. Platelet-derived growth factor-induced stabilization of cyclooxygenase 2 mRNA in rat smooth muscle cells requires the c-Src family of protein-tyrosine kinases. J Biol Chem 2007a;282:32699-709
85. Xu K, Shu HK. EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/ Sp3 transcription factors in human gliomas. Cancer Res 2007b;67:6121-9
86. Montuschi P, Sala A, Dahlen SE, Folco G. Pharmacological modulation of the leukotriene pathway in allergic airway disease. Drug Dis Today 2007;12:404-12
87. Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci 1993;90:11693-7
88. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol 1999;104:5-13
89. Picado C, Castillo JA, Montserrat JM, Agusti-Vidal A. Aspirin-intolerance as a precipitating factor of life-threatening attacks of asthma requiring mechanical entilation. Eur Respir J 1989;2:127-9
90. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990;3:588-93
91. Busse WW. The role of leukotrienes in asthma and allergic rhinitis. Clin Exp Allergy 1996;26:868-79
92. Sampson AP. The leukotrienes: mediators of chronic inflammation in asthma. Clin Exp Allergy 1996;26:995-1004
93. Sanak M, Sampson AP. Biosynthesis of cysteinyl-leucotrienes in aspirin-intolerant asthma. Clin Exp Allergy 1999;29:306-13
94. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353,inhibits aspirin-induced asthma. Am Rev Respir Dis 1991;144:957-8
95. Sestini P, Armetti L, Gambaro G, et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive 1996;153:572-5
96. Szczeklik A, Sladek K, Dworski RJ, et al. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1996;154:1608-14
97. Bianco S, Robuschi M, Petrigni G, et al. Efficacy and tolerability of nimesulide in asthmatic patients intolerant to aspirin. Drugs 1993;46:115-20
98. Kosnik M, Music E, Matjaz F, Suskovic S. Relative safety of meloxicam in NSAID-intolerant patients. Allergy 1998;53:1231-3
99. Dahlen B, Szczeklik A, Murray JJ. Celecoxib in patients with asthma and aspirin intolerance. The celecoxib in aspirin-intolerant asthma study group. N Engl J Med 2001;344:142
100. Martin-Garcia C, Hinojosa M, Berges P, et al. Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 2002;121:1812-17
101. Rowlinson SW, Kiefer JR, Prusakiewicz JJ, et al. A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J Biol Chem 2003;278:45763-9
102. Togias A, Naclerio RM, Proud D, et al. Mediator release during nasal provocation: a model to investigate the pathophysiology of rhinitis. Am J Med 1985;79:26-33
103. Van Adelsberg J, Philip G, LaForce CF, et al. Randomised controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003;90:214-22
104. Ranatunge RR, Augustyniak M, Bandarage UK. Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donorcontaining pyrazoles. J Med Chem 2004;47:2180-93
105. Ranatunge RR, Garvey DS, Janero DR. Synthesis and selective cyclooxygenase-2 (COX-2) inhibitory activity of a series of novel bicyclic pyrazoles. BioorgMed Chem 2004;12:1357-66
106. Ranatunge RR, Earl RA, Garvey DS. 3-(2-Methoxytetrahydrofuran-2-yl) pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors. Bioorg Med Chem Lett 2004;14:6049-52
107. Available from: http://clinicaltrials.gov/ ct2/show/NCT01002690